Regeneron and ModeX Therapeutics Form Multi-Billion-Dollar Alliance to Develop Multispecific Antibodies

Regeneron Pharmaceuticals has announced a strategic collaboration with ModeX Therapeutics, a subsidiary of OPKO Health, to develop multispecific antibody treatments designed to target multiple disease pathways within a single molecule. The agreement includes an upfront payment to ModeX of around seven million dollars, with potential milestone payments exceeding two hundred million dollars per program and a total deal value that could surpass one billion dollars if multiple products reach development milestones.

ModeX contributes its proprietary MSTAR platform, which enables the creation of antibodies with up to six binding sites in one construct. This technology is designed to address complex diseases such as cancer, autoimmune disorders and infectious diseases that involve multiple biological mechanisms. Regeneron will apply its expertise in antibody engineering, clinical development and global commercial operations to progress selected candidates.

The collaboration provides ModeX with validation of its multispecific approach and access to Regeneron’s development capabilities, while Regeneron expands its innovation pipeline in next-generation biologics. Together, the companies aim to accelerate the development of therapies capable of offering broader and more durable clinical benefits than traditional single-target biologics.